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Abstract The role of RGS proteins on dopaminergic D2S re-
ceptor (D2SR) signalling was investigated in Chinese hamster
ovary (CHO)-K1 cells, using recombinant RGS protein- and
PTX-insensitive GKo proteins. Dopamine-mediated [35S]GTPQS
binding was attenuated by more than 60% in CHO-K1 D2SR
cells coexpressing a RGS protein- and PTX-insensitive
GKoGly184Ser:Cys351Ile protein versus cells coexpressing a sim-
ilar amount of PTX-insensitive GKoCys351Ile protein. Dopa-
mine-agonist-mediated Ca2+ responses were dependent on the
coexpression with a GKoCys351Ile protein and were fully abol-
ished upon coexpression with a GKoGly184Ser:Cys351Ile protein.
These results suggest that interactions between the GKo protein
and RGS proteins are involved in e⁄cient D2SR signalling.
7 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
Key words: RGS; Dopamine D2 receptor;
G protein coupling; GTPQS; Ca2þ response
1. Introduction
Regulators of G protein signalling (RGS) proteins are
GTPase activating proteins (GAP) for GK protein subunits
of heterotrimeric G proteins [1,2]. First functionally identi¢ed
as GAP for the GKi subclass [3], RGS proteins have now been
described as GAP for three other GK protein subclasses GKq,
GK12=13 and GKs also [4^6]. RGS proteins, besides their role as
GAP, can play additional roles in cell signalling [7^9]. For
example RGS4 can behave as an e¡ector shield for GKq [4],
and p115RhoGEF as an e¡ector for GK13 [10]. Most previous
studies on RGS proteins emphasise their role as negative reg-
ulators in G protein signalling pathways. However, positive
e¡ects of overexpressed RGS proteins on G protein coupled
receptor (GPCR) signalling have also been reported. For ex-
ample RGS proteins have been shown to enhance the activa-
tion of Kþ channels [11^13], suggested to be caused by an
increase in availability of free GLQ subunits [14]. A positive
e¡ect of endogenous RGS proteins on signalling can be ex-
plained by considering that RGS proteins enhance the overall
e⁄cacy of the GDP/GTP binding cycle of the GK protein in a
receptor/GK protein/RGS complex [1]. Few studies on the
function of endogenous RGS proteins have emerged. Speci¢c
RGS knockouts in mice have de¢ned an important role for
RGS9-1 in vision [15], and similar studies implicated RGS2 in
phenomena as diverse as T cell activation, anxiety and aggres-
sive behaviour of mice [16], perhaps because of the diversity in
multiple possible GK protein partners for RGS2. Recently, a
ribozyme approach was used successfully to de¢ne receptor-
selective roles of endogenous RGS3 and RGS5 in smooth
muscle cells for muscarinic M3 receptor and angiotensin
AT1A receptor, respectively [17]. An alternative way to study
the role of RGS proteins in speci¢c G protein signalling path-
ways is to disrupt the GK/RGS interaction by mutation of
the GK subunit. Such a point mutation in GKo protein
(GKoGly184Ser) renders the mutant GKo protein insensitive to
RGS proteins, without a change in its GDP release, GTPQS
binding and intrinsic GTP hydrolysis parameters [18]. The
introduction of this mutation in GKo protein, in combination
with the C-terminal Cys351Ile (or Cys351Gly) mutation that
confers pertussis toxin (PTX) insensitivity [19], was shown
very useful to study the role of endogenous RGS proteins in
GKi=o coupled signalling pathways [20,21]. The dopamine D2
receptor (D2R) has been shown to couple via Gi=o to diverse
e¡ectors in di¡erent cell lines [22,23], and in Chinese hamster
ovary (CHO)-K1 cells speci¢cally D2R activation leads to an
increase in Ca2þ levels [24]. By abolishing the GKo protein/
RGS proteins interactions using the GKoGly184Ser:Cys351Ile
protein, we observed a decrease of D2SR signalling at the level
of GK protein activation ([35S]GTPQS binding) and second
messenger (Ca2þ response). This suggests that endogenous
RGS proteins play a positive role for e⁄cient signalling in a
receptor/G protein/RGS/e¡ector complex.
2. Materials and methods
2.1. Cloning of human dopamine D2 receptor
The short splice variant of the human D2R (RC: 2.1.DA.02) was
cloned as previously described [25] by PCR using oligonucleotide
primers designed according to the sequence deposited in the GenBank
database (accession number S69899).
2.2. Construction of rat GKo insensitive to PTX and RGS
Rat GKoCys351Ile protein (insensitive to PTX) was constructed as
described previously [19]. An additional point mutation Gly184Ser,
conferring insensitivity of GKo subunits to RGS proteins, was intro-
duced by using a Quick Change site-directed mutagenesis kit (Strata-
gene) according to the supplier’s instructions. Mutation was con-
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¢rmed by sequencing on ABI Prism 310 Genetic analyser using a Big
Dye Terminator Cycle Sequencing reaction kit.
2.3. Cell culture
CHO-K1 cell line stably expressing human D2SR (CHO-K1 D2SR)
was generated upon dilution of transfected cells (10- to 1000-fold) and
selection in Ham’s F12 plus 10% heat-inactivated foetal calf serum,
penicillin (65 Wg/ml), streptomycine (100 Wg/ml) and geneticin (1.25
mg/ml).
2.4. Membrane preparation
CHO-K1 D2SR cells were transfected with either GKoCys351Ile or
GKoGly184Ser:Cys351Ile in pCR3.1 plasmid using Lipofectamine (Gib-
co BRL) [26]. Cells were harvested 48 h after transfection. Treatment
with PTX (20 ng/ml) was performed during 16 h. Membrane prepa-
rations were performed as follows: cells were washed with phosphate
bu¡ered saline, stored at 380‡C, collected mechanically in Tris^HCl
10 mM/EDTA 0.1 mM (pH 7.5), homogenised and centrifuged twice
for 10 min at 45 000Ug. The ¢nal pellet was resuspended in the same
bu¡er and stored at 380‡C until further use.
2.5. [35S]GTPQS binding response
[35S]GTPQS binding on membrane preparations from CHO-K1 cells
was performed as described previously [27]. Brie£y, basal and agonist-
dependent [35S]GTPQS binding was performed with membranes incu-
bated at 25‡C with or without compound for 30 min in 20 mM
HEPES (pH 7.4) supplemented with 30 WM GDP, 100 mM NaCl,
3 mMMgCl2 and 0.2 mM ascorbic acid followed by addition of 0.5 nM
of [35S]GTPQS and another 30 min incubation. Basal [35S]GTPQS
binding was de¢ned as [35S]GTPQS binding obtained in absence of
compound. Activation of [35S]GTPQS binding was determined as the
percentage of increased basal [35S]GTPQS binding after stimulation
with compound. EC50 values were de¢ned as the concentration of
ligand yielding 50% of its own maximal [35S]GTPQS binding response.
Protein levels were quanti¢ed with a dye-binding assay kit (Bio-Rad),
using bovine serum albumin as a standard [28].
2.6. [3H]Nemonapride binding
Scatchard analysis was performed as described [25] using con-
centrations of radioligand [3H]nemonapride ranging from 3 pM to
3 nM. Membrane preparations were diluted in 50 mM Tris^HCl,
120 mM NaCl, 5 mM KCl, (pH 7.4). 10 WM of (+)-butaclamol was
used to determine non-speci¢c binding. The reactions were stopped
after 1 h incubation at 25‡C by addition of 3.0 ml of ice-cold 50 mM
Tris^HCl (pH 7.7) and rapid ¢ltration over Whatman GF/B glass
¢bre ¢lters using a Brandel harvester, washed and radioactivity was
counted.
2.7. Immunological detection
Total proteins (25 Wg) from CHO-K1 D2SR membranes transfected
with either GKoCys351Ile or GKoGly184Ser:Cys351Ile protein were sep-
arated in Tris^glycine SDS gels (12% w/v polyacrylamide) and electro-
transfered onto polyvinylidene di£uoride membranes. After blocking
in TBS^T [10 mM Tris^HCl (pH 7.4), 150 mM NaCl and 0.1% Tween
20 (v/v)]+5% of non-fat milk, the membranes were probed with a
polyclonal antibody (1:1000) raised against the whole rat GKo protein
(Calbiochem) in TBS^T+1% non-fat milk. Secondary antibody (anti-
rabbit immunoglobulin horseradish peroxidase conjugate, Amersham)
incubations and all washes were performed in TBS^T+1% non-fat
milk. Detection was performed by enhanced chemiluminescence
(Pierce) and exposure to Biomax ML ¢lm (Kodak). Densitometric
analysis was performed using a computer-based image analysis system
(AIS, Imaging Research).
2.8. Measurement of Ca2+ responses
CHO-K1 D2SR cells were transfected by electroporation [26] with
10 Wg of either empty pCR3.1 vector, GKoCys351Ile or
GKoGly184Ser:Cys351Ile (in pCR3.1). Treatment with PTX (20 ng/
ml) was performed during 16 h before Ca2þ measurement. Cells
were assayed 48 h post-transfection for Ca2þ responses after 1 h in-
cubation with 2 WM £uo-3 £uorescent calcium indicator dye as de-
scribed [26]. Fluorescent readings were made every 2 s for 3 min using
a £uorometric imaging plate reader (FLIPR, Molecular Devices).
Data for Ca2þ responses were expressed in arbitrary £uorescence units
(AFU) and were not translated into Ca2þ concentrations.
3. Results
The high-e⁄cacy dopaminergic agonists dopamine (DA)
and R(3)-propylnorapomorphine [(3)-NPA] produced an in-
crease of respectively 50T 8% and 65T13% over basal
[35S]GTPQS binding on CHO-K1 D2SR membranes expressing
the GKoCys351Ile protein and pretreated with PTX; the partial
Fig. 1. A: [35S]GTPQS binding response after stimulation with either
partial or high-e⁄cacy dopaminergic ligands on PTX-pretreated
CHO-K1 D2SR membranes coexpressing either GKoCys351Ile or
GKoGly184Ser:Cys351Ile protein. Results obtained after stimulation
with either DA 10 WM, (3)-NPA 1 WM or (+)-NPA 1 WM. The ag-
onists did not stimulate [35S]GTPQS binding on mock-transfected,
PTX-pretreated CHO-K1 D2SR membranes, whereas 10 WM of DA
stimulated basal [35S]GTPQS binding by 117T 10% on mock-trans-
fected CHO-K1 D2SR membrane in the absence of PTX-pretreat-
ment (data not shown). Statistical analysis was performed with one-
way analysis of variance followed by an all pairwise multiple com-
parison (Student^Newman^Keuls procedure). *Di¡erence statistical-
ly signi¢cant (P6 0.05) versus stimulation of DA on CHO-K1
D2SR membranes expressing GKoCys351Ile protein.
#Di¡erence sta-
tistically signi¢cant (P6 0.05) for CHO-K1 D2SR membranes ex-
pressing GKoGly184Ser:Cys351Ile protein versus stimulation obtained
with the same compound on CHO-K1 D2SR membranes expressing
GKoCys351Ile protein. B: Concentration-dependent [35S]GTPQS bind-
ing response of high-e⁄cacy agonist (3)-NPA on PTX-pretreated
CHO-K1 D2SR membranes coexpressing either GKoCys351Ile or
GKoGly184Ser:Cys351Ile protein. Data are expressed as percent of
stimulation of basal [35S]GTPQS binding (basal [35S]GTPQS binding
was 81T 9 fmol/mg of protein and 78T 4 fmol/mg of protein when
either GKoCys351Ile or GKoGly184Ser:Cys351Ile protein was coex-
pressed, respectively). Data are meanTS.E.M. of three to four inde-
pendent experiments, each performed in triplicate.
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agonist S(+)-propylnorapomorphine [(+)-NPA] displayed a
weak stimulation of 8 T 2% of basal [35S]GTPQS binding on
the same membranes (Fig. 1A). When CHO-K1 D2SR cells
expressed the GKoGly184Ser:Cys351Ile protein, instead of the
GKoCys351Ile protein, stimulation of [35S]GTPQS binding with
dopaminergic ligands was reduced by 64% and 62% for DA
and (3)-NPA respectively (Fig. 1A). In the same conditions,
(+)-NPA was unable to stimulate [35S]GTPQS binding (Fig.
1A). Concentration^response curves of the ligand (3)-NPA
for [35S]GTPQS binding revealed that the di¡erence observed
could be attributed to reduction in the e⁄cacy of D2SR and
GKo protein coupling, the ligand potency remaining un-
changed (EC50 was 2.7 T 0.4 nM and 3.3T 0.9 nM for CHO-
K1 D2SR cells expressing the GKoCys351Ile protein and the
GKoGly184Ser:Cys351Ile protein, respectively) (Fig. 1B). The
above results suggest that endogenous RGS proteins are nec-
essary for e⁄cient activation of recombinant GKo protein via
D2SR. Binding analyses of D2SR using [3H]nemonapride as a
radioligand revealed similar a⁄nities and receptor expression
levels : the Kd and Bmax were 56T 12 pM and 1.03T 0.10 pmol/
mg of protein respectively for CHO-K1 D2SR cells expressing
the GKoCys351Ile protein compared to 64T 21 pM and
1.10T 0.11 pmol/mg of protein respectively for CHO-K1
D2SR cells expressing the GKoGly184Ser:Cys351Ile protein.
Western blot analysis showed equal expression levels of
both GKoCys351Ile and GKoGly184Ser:Cys351Ile protein (at ap-
proximately 40 kDa, Fig. 2; in agreement with its theorical
molecular weight calculated from its published sequence, Gen-
Bank database accession number M17526). D2SR signalling
was also monitored measuring Ca2þ responses. The agonists
DA and (3)-NPA induced a strong increase of Ca2þ response
(2698T 439 AFU and 2908T 303 AFU respectively, Fig. 3A)
in CHO-K1 D2SR cells transfected with the empty pCR3.1
plasmid. This response was totally abolished by PTX pretreat-
ment (Fig. 3A), con¢rming that this is a Gi=o and not a Gq=11
protein-mediated event in this experimental system. Expres-
sion of GKoCys351Ile protein in CHO-K1 D2SR cells restored
a PTX-insensitive, DA-mediated Ca2þ response (1620T 314
and 1763T 217 AFU after DA and (3)-NPA stimulation,
respectively) (Fig. 3B). By contrast, expression of
GKoGly184Ser:Cys351Ile protein in CHO-K1 D2SR cells was
unable to restore PTX-insensitive, DA-mediated Ca2þ re-
sponse (Fig. 3B).
4. Discussion
The role of endogenous RGS proteins on the signalling
e⁄cacy of the GKo-coupled D2SR was investigated using
PTX-insensitive GKo subunits unable to interact with RGS
proteins. In CHO-K1 cells, D2R occupation by dopaminergic
agonists activates Gi=o signalling pathways, typically leading
to inhibition of adenylyl cyclase activity and Ca2þ response
[24], increase of arachidonic acid release [29], stimulation of
the Naþ/Hþ exchanger and mitogenesis [30]. By abolishing the
GKo protein/RGS proteins interactions and inactivating en-
dogenous GKi=o subunits, we observed a signi¢cant drop in
the magnitude of agonist-dependent D2R signalling at the
level of GK protein activation ([35S]GTPQS binding) as well
as at the level of a second messenger production (Ca2þ re-
sponse) in CHO-K1 cells. We did not observe a change in the
potency for the agonist (3)-NPA (Fig. 1B). Also the a⁄nity
of (3)-NPA for the D2R (measured by displacement of
[3H]nemonapride) was similar in the case of GKoCys351Ile pro-
tein coexpression and GKoGly184Ser:Cys351Ile protein coex-
pression (data not shown). Neither D2R nor G protein ex-
pression levels displayed a di¡erence, and the observed
decrease in coupling is unlikely to result from a di¡erence in
[35S]GTPQS binding due to the Gly184Ser mutation as com-
pared to the wild type GKo subunit. In fact, Lan and co-work-
Fig. 2. Immunological detection of GKo proteins in membrane prep-
arations of CHO-K1 D2SR cells transfected with either empty
pCR3.1 plasmid (mock), GKoCys351Ile or GKoGly184Ser:Cys351Ile
plasmid, PTX pretreated. Molecular weights are indicated in the left
margin. Quanti¢cation (percentage versus GKoCys351Ile protein upon
subtraction of the background), was 105% for the GKoGly184Ser:
Cys351Ile protein. A rectangle covering the signal of GKoCys351Ile
protein was identically reproduced as surface template for the quan-
ti¢cation of the GKoGly184Ser:Cys351Ile protein.
Fig. 3. A: Ca2þ response after 10 WM DA stimulation of CHO-K1
D2SR cells transfected with the empty pCR3.1 plasmid, cells non-
pretreated or pretreated with PTX. B: 10 WM DA modulation of
Ca2þ response of CHO-K1 D2SR cells expressing either GKoCys351Ile
or GKoGly184Ser:Cys351Ile protein, cells were pretreated with PTX.
Results are expressed in AFU. One representative experiment out of
four independent experiments, each experimental point performed in
quadruplicate, is shown. For each condition Ca2þ response obtained
with 1 WM (3)-NPA was similar to response observed with 10 WM
DA (data not shown).
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ers [18] have described that this mutation does modify neither
GDP release, GTPQS binding nor GTP hydrolysis. It is un-
likely that the Gly184Ser mutation directly in£uences recep-
tor^G protein coupling; the position of Gly184 in the ¢rst
switch region of the GK subunit has never been described
for making receptor contacts, but rather for being stabilised
by RGS domains [31]. Furthermore, since GTPQS is con-
sidered as a non-hydrolysable analogue of GTP, we presume
that the present observation is independent from the GAP
activity of RGS proteins that may interact with GKo proteins.
From the present results it appears that RGS proteins facili-
tate D2SR:GKo protein coupling, probably because RGS pro-
teins increase the pool of GKo proteins available for activa-
tion.
Reasoning along lines of RGS-GAP activity does not ex-
plain our observations. Indeed, if the GKo subunit can no
more interact with RGS proteins, it should stay active
(GTP-bound) a longer time and thus show enhanced signal-
ling towards e¡ectors. The surprising fact that we observed
decreased signalling e⁄cacy can be explained in the context
of a multiprotein complex. This complex comprises receptor,
G protein and RGS protein, in which the G protein/RGS
protein interaction is implicated in the activation of the G
protein by the receptor. In a reconstituted phospholipid sys-
tem (containing GKi1 protein and muscarinic M2 receptor) at
steady state, the addition of RGS4 increases the rate of re-
ceptor-catalysed GDP/GTP exchange (measured by an in-
crease of GTPQS binding) [1]. According to the theory of
Ross and Wilkie [1] the presence of a RGS protein in the
cycle of activation/deactivation of GPCR signalling could
also allow the G protein to activate and deactivate without
receptor dissociation and thereby favour the overall cycle ac-
tivation. Thus, the absence of G protein/RGS interaction in a
receptor/G protein/RGS protein complex may lead to an al-
teration of receptor-catalysed GTPQS loading and a decrease
in signalisation mediated by GPCR, which is what we ob-
served.
Although many RGS proteins show a⁄nity and in vitro
GAP activity towards GKo subunits, the functional RGS
partner for GKo protein in our CHO-K1 system remains un-
known. By reverse transcription polymerase chain reaction
RGS1, RGS2, RGS3, RGS16 and RGS-GAIP mRNAs
were shown to be present in CHO-K1 cells [32] and we addi-
tionally detected RGS10 mRNA (data not shown). From in
vitro studies, RGS12 [33] and RGS14 [34] also seem good
candidates; especially RGS12 with its multiple protein bind-
ing modules [35] would lend itself well as a sca¡olding protein
to increase signalling e⁄cacy at the plasma membrane. Sim-
ilarly it was shown for RGS4 and for RGS-GAIP that do-
mains outside their RGS domain may confer receptor speci-
¢city and thus contribute to the e⁄cacy of Ca2þ signalling
[36,37].
In conclusion, positive e¡ects of RGS proteins on receptor
signalling have until now been observed in the frame of en-
hanced kinetics of Kþ-channel activation [38]. The present
study expands this notion and suggests a positive role for
RGS proteins in e⁄cacy of GPCR signalling.
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